Regeneron Pharmaceuticals (REGN) Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for REGN from our risk checks.
REGN Community Fair Values
Create NarrativeSee what 159 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$783.65 |
| 52 Week High | US$821.11 |
| 52 Week Low | US$476.49 |
| Beta | 0.41 |
| 1 Month Change | 3.26% |
| 3 Month Change | 13.00% |
| 1 Year Change | 16.22% |
| 3 Year Change | 6.43% |
| 5 Year Change | 64.28% |
| Change since IPO | 3,609.59% |
Recent News & Updates
Recent updates
Regeneron: Expect Double-Digit Growth In 2026
Jan 31Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Nov 19
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Nov 09Regeneron: Still A Biotech Juggernaut
Apr 16Dupixent And EYLEA Will Open New Therapeutic Frontiers
Promising pipeline and Dupixent’s market expansion are expected to drive revenue growth and improve net margins.Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Apr 06Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Mar 14Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Feb 04Regeneron: Phase III Success In Skin Cancer For Libtayo
Jan 15Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
Jan 05Shareholder Returns
| REGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.2% | 1.3% | 0.5% |
| 1Y | 16.2% | 25.7% | 10.7% |
Return vs Industry: REGN underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: REGN exceeded the US Market which returned 10.7% over the past year.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: REGN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 15,410 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | US$79.94b |
| Earnings (TTM) | US$4.50b |
| Revenue (TTM) | US$14.34b |
Is REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$14.34b |
| Cost of Revenue | US$7.95b |
| Gross Profit | US$6.39b |
| Other Expenses | US$1.89b |
| Earnings | US$4.50b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.90 |
| Gross Margin | 44.57% |
| Net Profit Margin | 31.41% |
| Debt/Equity Ratio | 6.4% |
How did REGN perform over the long term?
See historical performance and comparisonDividends
Does REGN pay a reliable dividends?
See REGN dividend history and benchmarks| Regeneron Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Feb 20 2026 |
| Dividend Pay Date | Mar 05 2026 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 20 days |
Does REGN pay a reliable dividends?
See REGN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 22:54 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 50 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |